Trevena (NASDAQ:TRVN) is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system disorders, with a primary focus on pain management. Headquartered in King of Prussia, Pennsylvania, Trevena leverages its proprietary Mobius™ G protein–biased receptor ligand platform to discover and develop small-molecule medicines designed to improve the safety, efficacy and tolerability profile of existing treatment classes. The company completed its initial public offering in 2014 and trades on the NASDAQ under the symbol TRVN.
The company’s lead candidate is oliceridine (marketed as OLINVO™), a selective μ-opioid receptor agonist designed to provide rapid onset analgesia with a differentiated safety profile compared to traditional opioids. OLINVO™ has been evaluated in multiple pivotal clinical trials for the management of moderate to severe acute pain, including postoperative and emergency department settings. Alongside oliceridine, Trevena is advancing additional pipeline programs, such as TRV734 for pain indications with oral dosing potential and TRV027 for cardiovascular and renal disorders, each engineered to exploit biased signaling pathways for improved therapeutic windows.
Since its founding in 2007, Trevena has applied its Mobius™ platform to identify and optimize compounds that selectively engage G protein signaling while minimizing recruitment of β-arrestin pathways, which are associated with adverse events. This approach aims to transform the treatment landscape for conditions where safety and tolerability limit patient outcomes. The company’s research and development operations span its Pennsylvania headquarters, with strategic collaborations and partnerships extending its reach into Europe, Latin America and Asia-Pacific markets.
Trevena is led by an experienced management team with backgrounds in both biotech innovation and pharmaceutical commercialization. President and Chief Executive Officer Jay P. Siegel guides the company’s strategic priorities, and the board includes industry veterans in drug development, regulatory affairs and global market access. Through its focused pipeline, proprietary platform and seasoned leadership, Trevena is positioned to address unmet medical needs and deliver meaningful advances in central nervous system therapies.
